Commercial biopharmaceutical company specializing in immune globulin products.
ADMA Biologics, Inc., headquartered in Ramsey, New Jersey, is a leading biopharmaceutical company dedicated to the development, manufacturing, and global distribution of specialty plasma-derived biologics. The company focuses on addressing immune deficiencies and infectious diseases through its innovative product portfolio. ADMA Biologics' offerings include BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI), and ASCENIV, another IVIG product designed for the same indication.
In addition to BIVIGAM and ASCENIV, ADMA Biologics manufactures Nabi-HB, a product utilized in the treatment of acute exposure to blood containing Hepatitis B surface antigen, among other specified exposures to Hepatitis B. The company is actively advancing a pipeline of plasma-derived therapeutics, focusing on methods for the treatment and prevention of infections caused by S. pneumoniae through immunoglobulin therapies.
Beyond its product development efforts, ADMA Biologics operates source plasma collection facilities to support its manufacturing operations and ensure a reliable supply chain. The company markets its products through a network of independent distributors, sales agents, specialty pharmacies, and other alternate site providers, ensuring broad accessibility to its therapies.
Established in 2004, ADMA Biologics continues to expand its global footprint and therapeutic capabilities. With a commitment to scientific excellence and patient care, the company remains at the forefront of advancing plasma-derived biologics, addressing critical medical needs and improving the quality of life for patients worldwide.